Applying a "double-feature" promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery

Tamás I. Orbán, Ágota Apáti, Andrea Németh, Nóra Varga, Virág Krizsik, Anita Schamberger, Kornélia Szebényi, Zsuzsa Erdei, György Várady, Éva Karászi, László Homolya, Katalin Német, Elen Gócza, Csaba Miskey, Lajos Mátés, Zoltán Ivics, Zsuzsanna Izsvák, Balázs Sarkadi

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Human embryonic stem (HuES) cells represent a new potential tool for cell-therapy and gene-therapy applications. However, these approaches require the development of efficient, stable gene delivery, and proper progenitor cell and tissue separation methods. In HuES cell lines, we have generated stable, enhanced green fluorescent protein (EGFP)-expressing clones using a transposon-based (Sleeping Beauty) system. This method yielded high percentage of transgene integration and expression. Similarly to a lentiviral expression system, both the undifferentiated state and the differentiation pattern of the HuES cells were preserved. By using the CAG promoter, in contrast to several other constitutive promoter sequences (such as CMV, elongation factor 1α, or phosphoglycerate kinase), an exceptionally high EGFP expression was observed in differentiated cardiomyocytes. This phenomenon was independent of the transgene sequence, methods of gene delivery, copy number, and the integration sites. This "double-feature" promoter behavior, that is providing a selectable marker for transgene expressing undifferentiated stem cells, and also specifically labeling differentiated cardiomyocytes, was assessed by transcriptional profiling. We found a positive correlation between CAG promoter-driven EGFP transcription and expression of cardiomyocyte-specific genes. Our experiments indicate an efficient applicability of transposon-based gene delivery into HuES cells and provide a novel approach to identify differentiated tissues by exploiting a nontypical behavior of a constitutively active promoter, thereby avoiding invasive drug selection methods.

Original languageEnglish
Pages (from-to)1077-1087
Number of pages11
JournalStem Cells
Volume27
Issue number5
DOIs
Publication statusPublished - May 1 2009

Keywords

  • "Double-feature" promoter
  • CAG promoter
  • Cardiomyocytes
  • Human embryonic stem cells
  • Lentiviral gene delivery
  • Sleeping beauty transposon

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Applying a "double-feature" promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery'. Together they form a unique fingerprint.

  • Cite this

    Orbán, T. I., Apáti, Á., Németh, A., Varga, N., Krizsik, V., Schamberger, A., Szebényi, K., Erdei, Z., Várady, G., Karászi, É., Homolya, L., Német, K., Gócza, E., Miskey, C., Mátés, L., Ivics, Z., Izsvák, Z., & Sarkadi, B. (2009). Applying a "double-feature" promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery. Stem Cells, 27(5), 1077-1087. https://doi.org/10.1002/stem.45